Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Kieran Docherty MB ChB, PhD

Kieran F. Docherty MB ChB, PhD

Clinical Senior Lecturer, British Heart Foundation Glasgow Cardiovascular Research Centre, University of Glasgow, United Kingdom

Disclosures

Dr Docherty’s employer, the University of Glasgow, has been remunerated by AstraZeneca for his work on clinical trials; he has received speaker fees from AstraZeneca, Boehringer Ingelheim, Pharmacosmos, Translational Medical Academy and Radcliffe Cardiology; has served on Advisory Boards for Us2.ai and holds equity in the company, has served on an advisory board and served on a clinical endpoint committee for Bayer AG;; and has received research grant support (paid to his institution) from AstraZeneca, Roche, Novartis and Boehringer Ingelheim.

Recent Contributions to PracticeUpdate:

  1. Effects of Finerenone With and Without Concomitant SGLT2 Inhibitor Use in Patients With Heart Failure
  2. Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in Individuals With Overweight/Obesity but Without Diabetes
  3. Association of Prediabetes With Risk of Heart Failure in Patients With Atrial Fibrillation
  4. Severe Hypoglycemia and Heart Failure Incidence in Type 2 Diabetes

Most Read This Week

Recently Updated